A female patient presents to you with severe persistent asthma experiencing tachycardia, nausea, and jitteriness. She understands that her medication requires measuring serum levels. As you scan her current medications, which therapy is most likely the source of these undesirable side effects?

Rationale: A. Zileuton is a leukotriene synthesis inhibitor used for the chronic management of asthma, but it does not typically cause tachycardia or jitteriness. Its primary safety concerns involve potential hepatotoxicity, necessitating the monitoring of liver function tests (ALT) rather than therapeutic drug levels in the blood. It does not possess the stimulant-like properties described in the patient's current clinical presentation. B. Theophylline is a methylxanthine with a very narrow therapeutic index, meaning the dose required for bronchodilation is close to the dose that causes toxicity. Tachycardia, nausea, and CNS excitation (jitteriness) are classic hallmark signs of elevated serum theophylline levels. Because its metabolism is highly variable and affected by many factors, frequent serum concentration monitoring is mandatory to prevent life-threatening cardiac arrhythmias or seizures. C. While oral prednisone can cause mood changes and insomnia, it is not standard practice to measure serum levels of the drug to manage its effects. Prednisone side effects are typically managed by dose titration and monitoring for long-term complications like hyperglycemia or osteoporosis. It would not be the medication described as "requiring measuring serum levels" in a routine asthma management context. D. Ipratropium is a quaternary ammonium compound that is poorly absorbed into the systemic circulation when inhaled, resulting in minimal systemic side effects. It works locally to block muscarinic receptors in the lungs and does not cause significant tachycardia or systemic jitteriness at standard doses. It is used as a bronchodilator but does not require any form of therapeutic drug monitoring or blood testing.